Focusing on developing next-generation immunotherapies, specializes in T cell engager technology. Develops tumor activated immunotherapeutics, aiming to expand the therapeutic window. Leverages proprietary Tumor Activated T Cell Engager (TACTr) platform. Designs innovative drug candidates to treat various cancers. Constructs unique molecules with potential to enhance efficacy and reduce systemic toxicity. Seeks to transform treatment paradigms for patients with difficult-to-treat cancers. Builds a pipeline of novel therapies designed to overcome limitations of existing cancer treatments.